PLx Pharma (FRA:1D5A) Pre-Tax Income : €-26.44 Mil (TTM As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. PLx Pharma's pretax income for the three months ended in Sep. 2022 was €-8.58 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2022 was €-26.44 Mil. PLx Pharma's pretax margin was -2,200.51%.

PLx Pharma Pre-Tax Income Historical Data

The historical data trend for PLx Pharma's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Pre-Tax Income Chart

PLx Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Pre-Tax Income

Get a 7-Day Free Trial

-13.75

0.79

-18.45

-12.50

-40.82

PLx Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Pre-Tax Income	Get a 7-Day Free Trial															-18.40	3.15	-9.79	-11.22	-8.58

Competitive Comparison of PLx Pharma's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PLx Pharma's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where PLx Pharma's Pre-Tax Income falls into.

PLx Pharma Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

PLx Pharma's Pretax Income for the fiscal year that ended in Dec. 2021 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-36.099	+	-4.722	+	0	+	0	+	0
	=	-40.82

PLx Pharma's Pretax Income for the quarter that ended in Sep. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-10.947	+	2.245	+	0	+	0	+	0.12
	=	-8.58

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-26.44 Mil.

PLx Pharma (FRA:1D5A) Pre-Tax Income Explanation

PLx Pharma's Pretax Margin for the quarter that ended in Sep. 2022 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-8.582	/	0.39
	=	-2,200.51%

PLx Pharma Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of PLx Pharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

PLx Pharma (FRA:1D5A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines